Genmab A/S (GMAB) News Today → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free GMAB Stock Alerts $29.98 +0.33 (+1.11%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15, 2024 | finance.yahoo.comMarket Chatter: Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'May 14, 2024 | businesswire.comGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) CongressMay 13, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramMay 11, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Sold by Natixis Advisors L.P.Natixis Advisors L.P. reduced its position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 18.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 187,798 shares of the company's stock aftMay 9, 2024 | americanbankingnews.comGenmab A/S (NASDAQ:GMAB) Receives Consensus Recommendation of "Hold" from AnalystsMay 7, 2024 | globenewswire.comCapital Increase in Genmab as a Result of Employee Warrant ExerciseMay 3, 2024 | markets.businessinsider.comOptimistic Outlook for Genmab: Strategic Growth and Product Performance Underpin Buy RatingMay 3, 2024 | finance.yahoo.comGenmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call TranscriptMay 2, 2024 | seekingalpha.comGenmab A/S 2024 Q1 - Results - Earnings Call PresentationMay 2, 2024 | globenewswire.comGenmab Announces Financial Results for the First Quarter of 2024May 1, 2024 | seekingalpha.comGenmab: A Complicated TaleApril 30, 2024 | marketbeat.comShort Interest in Genmab A/S (NASDAQ:GMAB) Grows By 9.6%Genmab A/S (NASDAQ:GMAB - Get Free Report) was the recipient of a significant increase in short interest during the month of April. As of April 15th, there was short interest totalling 2,630,000 shares, an increase of 9.6% from the March 31st total of 2,400,000 shares. Based on an average trading volume of 575,800 shares, the days-to-cover ratio is presently 4.6 days. Approximately 0.4% of the shares of the company are short sold.April 30, 2024 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Genmab A/S (NASDAQ:GMAB)HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a report on Tuesday.April 30, 2024 | msn.comPfizer, Genmab cervical cancer therapy wins full FDA approvalApril 29, 2024 | businesswire.comFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical CancerApril 29, 2024 | businesswire.comTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerApril 29, 2024 | globenewswire.comTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerApril 29, 2024 | globenewswire.comTransactions in Connection with Share Buy-back Program GenmabApril 22, 2024 | globenewswire.comTransactions in Connection with Share Buy-back Program GenmabApril 20, 2024 | finance.yahoo.comGenmab A/S (GMAB)April 20, 2024 | marketbeat.comCerity Partners LLC Acquires 42,661 Shares of Genmab A/S (NASDAQ:GMAB)Cerity Partners LLC grew its holdings in Genmab A/S (NASDAQ:GMAB - Free Report) by 344.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 55,053 shares of the company's stock after purchasinApril 19, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) to Post FY2024 Earnings of $0.88 Per Share, William Blair ForecastsGenmab A/S (NASDAQ:GMAB - Free Report) - William Blair dropped their FY2024 earnings per share estimates for Genmab A/S in a note issued to investors on Wednesday, April 17th. William Blair analyst M. Phipps now anticipates that the company will post earnings per share of $0.88 for the year, downApril 17, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.43Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.43April 16, 2024 | finanznachrichten.deGenmab A/S: Genmab Announces Net Sales of DARZALEX (daratumumab) for First Quarter of 2024April 16, 2024 | globenewswire.comGenmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024April 15, 2024 | globenewswire.comTransactions in Connection with Share Buy-back Program GenmabApril 14, 2024 | marketbeat.comShort Interest in Genmab A/S (NASDAQ:GMAB) Increases By 17.1%Genmab A/S (NASDAQ:GMAB - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 2,400,000 shares, a growth of 17.1% from the March 15th total of 2,050,000 shares. Based on an average trading volume of 626,600 shares, the short-interest ratio is currently 3.8 days. Currently, 0.4% of the company's shares are sold short.April 14, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Acquired by NewEdge Wealth LLCNewEdge Wealth LLC increased its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 50.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 119,989 shares of the company's stock after acquiring an additional 40,382 shares during tApril 14, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Given Consensus Rating of "Hold" by BrokeragesShares of Genmab A/S (NASDAQ:GMAB - Get Free Report) have been given a consensus rating of "Hold" by the thirteen brokerages that are covering the company, Marketbeat.com reports. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and eight haApril 12, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Stake Trimmed by Hardman Johnston Global Advisors LLCHardman Johnston Global Advisors LLC lowered its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 18.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 482,657 shares of the company's stock after selApril 8, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramApril 8, 2024 | marketbeat.comBrokers Offer Predictions for Genmab A/S's FY2025 Earnings (NASDAQ:GMAB)Genmab A/S (NASDAQ:GMAB - Free Report) - Equities research analysts at William Blair cut their FY2025 earnings estimates for shares of Genmab A/S in a note issued to investors on Wednesday, April 3rd. William Blair analyst M. Phipps now expects that the company will post earnings of $1.07 per shaApril 5, 2024 | marketbeat.com185,698 Shares in Genmab A/S (NASDAQ:GMAB) Acquired by ANTIPODES PARTNERS LtdANTIPODES PARTNERS Ltd purchased a new position in shares of Genmab A/S (NASDAQ:GMAB - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 185,698 shares of the company's stock, valued at approximateApril 5, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Expected to Earn Q2 2024 Earnings of $0.28 Per ShareGenmab A/S (NASDAQ:GMAB - Free Report) - William Blair reduced their Q2 2024 earnings per share (EPS) estimates for shares of Genmab A/S in a research note issued on Wednesday, April 3rd. William Blair analyst M. Phipps now anticipates that the company will post earnings of $0.28 per share for thApril 5, 2024 | benzinga.comGenmab Stock (NASDAQ:GMAB), Quotes and News SummaryApril 4, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Gap Up to $29.30Genmab A/S (NASDAQ:GMAB) Shares Gap Up to $29.30April 3, 2024 | msn.comGenmab Buys Ovarian Cancer Drug Developer for $1.8 BillionApril 3, 2024 | bizjournals.comProfoundBio to be acquired by Danish biotech giant Genmab for $1.8 billionApril 3, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.96Genmab A/S (NASDAQ:GMAB) Shares Gap Down to $29.96April 3, 2024 | msn.comM&A News: Genmab (NASDAQ:GMAB) Is Acquiring ProfoundBio for $1.8BApril 3, 2024 | finance.yahoo.comGenmab Takes The Next Step In Its 'Evolution' With A $1.8 Billion TakeoverApril 3, 2024 | investopedia.comGenmab Buys ProfoundBio for $1.8B to Boost Oncology PortfolioApril 3, 2024 | msn.comGenmab to purchase US-based biotech company ProfoundBio for $1.8 billion in all-cash dealApril 3, 2024 | finance.yahoo.comGenmab Strengthens Oncology Portfolio With $1.8 Bln Acquisition of ProfoundBioApril 3, 2024 | reuters.comDenmark's Genmab to acquire ProfoundBio for $1.8 billionApril 3, 2024 | businesswire.comGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBioApril 3, 2024 | globenewswire.comGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBioApril 2, 2024 | marketbeat.comShort Interest in Genmab A/S (NASDAQ:GMAB) Grows By 10.2%Genmab A/S (NASDAQ:GMAB - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 2,050,000 shares, an increase of 10.2% from the February 29th total of 1,860,000 shares. Based on an average trading volume of 623,600 shares, the short-interest ratio is currently 3.3 days. Currently, 0.3% of the shares of the company are short sold.April 2, 2024 | globenewswire.comTransactions in Connection with Share Buy-back ProgramMarch 27, 2024 | marketbeat.comGenmab A/S (NASDAQ:GMAB) Receives Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research report on Wednesday. Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address get a piece of the profit from this land (Ad)This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land. Click here to see my #1 investment for 2024. GMAB Media Mentions By Week GMAB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GMAB News Sentiment▼0.870.42▲Average Medical News Sentiment GMAB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GMAB Articles This Week▼34▲GMAB Articles Average Week Get Genmab A/S News Delivered to You Automatically Sign up to receive the latest news and ratings for GMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Teva Pharmaceutical Industries News Today Alnylam Pharmaceuticals News Today BeiGene News Today BioMarin Pharmaceutical News Today Viatris News Today Sarepta Therapeutics News Today United Therapeutics News Today Dr. Reddy's Laboratories News Today Catalent News Today Roivant Sciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GMAB) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressMan who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the Markets[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
